Vanitha Sekar

1.8k citations

33 papers · 1.5k indexed · h-index 19

Impact in

Virology top 1%
- HIV Research and Treatment
Hepatology top 1%
- Hepatitis C virus research

Papers in ⓘ

Virology 18
- HIV Research and Treatment 18
Infectious Diseases 28
- HIV/AIDS drug development and treatment 28
- HIV/AIDS Research and Interventions 4

Co-authors: Richard M. W. Hoetelmans (19 shared papers)Éric Lefebvre (12 shared papers)Monika Peeters (7 shared papers)Martine De Pauw (13 shared papers)Goedele De Smedt (4 shared papers)Tony Vangeneugden (10 shared papers)David Back (2 shared papers)Oliver Lenz (4 shared papers)
Journals: Antiviral Therapy (6 papers)Antimicrobial Agents and Chemotherapy (3 papers)British Journal of Clinical Pharmacology (3 papers)AIDS (2 papers)The Journal of Clinical Pharmacology (2 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Vanitha Sekar

33 papers receiving 1.4k citations

Peers

Countries citing papers authored by Vanitha Sekar

Since Specialization

Citations

This map shows the geographic impact of Vanitha Sekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanitha Sekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanitha Sekar more than expected).

Fields of papers citing papers by Vanitha Sekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanitha Sekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanitha Sekar. The network helps show where Vanitha Sekar may publish in the future.

Co-authors

The 25 scholars most cited alongside Vanitha Sekar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vanitha Sekar Line = papers co-authored together Vanitha Sekar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study Hepatology ·Michael Fried, Marı́a Buti, Gregory J. Dore, Robert Flisiak, Péter Ferenci, Ira M. Jacobson, Patrick Marcellin, Michael P. Manns, И. Г. Никитин, Fred Poordad, Morris Sherman, Stefan Zeuzem, Jane Scott, Leen Gilles, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Maria Beumont‐Mauviel	2013	224
2	Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS ·Anthony Mills, Mark Nelson, Dushyantha Jayaweera, Kiat Ruxrungtham, Isabel Cassetti, Pierre-Marie Girard, Cassy Workman, Inge Dierynck, Vanitha Sekar, Carline Vanden Abeele, Ludo Lavreys	2009	199
3	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial Gastroenterology ·Stefan Zeuzem, Thomas Berg, Edward Gane, Peter Ferenci, Graham R. Foster, Michael Fried, Christophe Hézode, Gideon M. Hirschfield, Ira M. Jacobson, И. Г. Никитин, Paul J. Pockros, Fred Poordad, Jane Scott, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Rekha Sinha, Maria Beumont‐Mauviel	2013	184
4	Darunavir: Pharmacokinetics and Drug Interactions Antiviral Therapy ·David Back, Vanitha Sekar, Richard M. W. Hoetelmans	2008	95
5	Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers Antiviral Therapy ·Monika Schöller‐Gyüre, Thomas N. Kakuda, Vanitha Sekar, Brian Woodfall, Goedele De Smedt, Éric Lefebvre, Monika Peeters, Richard M. W. Hoetelmans	2007	88
6	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study Journal of Hepatology ·Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt	2012	86
7	The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers The Journal of Clinical Pharmacology ·Vanitha Sekar, Dries Kestens, Sabrina Spinosa‐Guzman, Martine De Pauw, Els De Paepe, Tony Vangeneugden, Éric Lefebvre, Richard M. W. Hoetelmans	2007	72
8	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial Antiviral Therapy ·Michael P. Manns, H. W. Reesink, Thomas Berg, Geoffrey Dusheiko, Robert Flisiak, Patrick Marcellin, Christophe Moreno, Oliver Lenz, Paul Meyvisch, Monika Peeters, Vanitha Sekar, Kenneth Simmen, René Verloes	2011	57
9	Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers British Journal of Clinical Pharmacology ·Richard M. W. Hoetelmans, Kris Mariën, Martine De Pauw, Andrew Hill, Monika Peeters, Vanitha Sekar, Piet De Doncker, Brian Woodfall, Éric Lefebvre	2007	41
10	Pharmacokinetic Interaction between Darunavir Boosted with Ritonavir and Omeprazole or Ranitidine in Human Immunodeficiency Virus-Negative Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Vanitha Sekar, Éric Lefebvre, Els De Paepe, Tine De Marez, Martine De Pauw, Wim Parys, Richard M. W. Hoetelmans	2007	39
11	Pharmacokinetic Interaction between Ethinyl Estradiol, Norethindrone and Darunavir with Low-Dose Ritonavir in Healthy Women Antiviral Therapy ·Vanitha Sekar, Éric Lefebvre, Sabrina Spinosa Guzman, Elise Felicione, Martine De Pauw, Tony Vangeneugden, Richard M. W. Hoetelmans	2008	39
12	Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents AIDS ·Stéphane Blanche, Rosa Bologna, Pedro Cahn, Sorin Rugină, Patricia M. Flynn, Clàudia Fortuny, Peter Vis, Vanitha Sekar, Ben Van Baelen, Inge Dierynck, Sabrina Spinosa‐Guzman	2009	37
13	Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers Antimicrobial Agents and Chemotherapy ·Vanitha Sekar, Ludo Lavreys, Tom Van de Casteele, Cindy Berckmans, Sabrina Spinosa‐Guzman, Tony Vangeneugden, Martine De Pauw, Richard M. W. Hoetelmans	2010	37
14	Pharmacokinetics of darunavir/ritonavir and ketoconazole following co‐administration in HIV–healthy volunteers British Journal of Clinical Pharmacology ·Vanitha Sekar, Éric Lefebvre, Martine De Pauw, Tony Vangeneugden, Richard M. W. Hoetelmans	2008	30
15	Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials Antimicrobial Agents and Chemotherapy ·Thomas N. Kakuda, Sylvie Abel, John D. Davis, Julia Hamlin, Monika Schöller‐Gyüre, Rebecca Mack, Noella Ndongo, Wendy Petit, Caroline E. Ridgway, Vanitha Sekar, Sarah Tweedy, Richard M. W. Hoetelmans	2011	29
16	Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial AIDS Research and Treatment ·Thomas N. Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert J. Ryan, David Anderson, Guy De La Rosa, Joseph Mrus	2012	28
17	Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers Antiviral Therapy ·Vanitha Sekar, Martine De Pauw, Kris Mariën, Monika Peeters, Éric Lefebvre, Richard M. W. Hoetelmans	2007	23
18	Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anita Mathias, John E. Hinkle, Gong Shen, Jeff Enejosa, Peter J. Piliero, Vanitha Sekar, Rebecca Mack, Frank Tomaka, Brian P. Kearney	2008	19
19	Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers Drugs in R&D ·Vanitha Sekar, Éric Lefebvre, Tine De Marez, Sabrina Spinosa‐Guzman, Martine De Pauw, Els De Paepe, Tony Vangeneugden, Richard M. W. Hoetelmans	2007	19
20	Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers Therapeutic Drug Monitoring ·Vanitha Sekar, Éric Lefebvre, Kris Mariën, Martine De Pauw, Tony Vangeneugden, Richard M. W. Hoetelmans	2007	17

About Vanitha Sekar

Vanitha Sekar is a scholar working on Virology, Infectious Diseases, Hepatology, Pediatrics, Perinatology and Child Health and Emergency Medicine, having authored 33 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (18 papers), Pharmacological Effects and Toxicity Studies (14 papers), Hepatitis C virus research (8 papers), HIV/AIDS Research and Interventions (4 papers), HIV-related health complications and treatments (3 papers), Hepatitis B Virus Studies (3 papers) and Pneumocystis jirovecii pneumonia detection and treatment (2 papers). The work is most often cited by research in Virology (537 citations), Hepatology (613 citations), Infectious Diseases (954 citations), Emergency Medicine (195 citations) and Epidemiology (633 citations). Vanitha Sekar has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Richard M. W. Hoetelmans, Éric Lefebvre, Monika Peeters, Martine De Pauw, Goedele De Smedt, Tony Vangeneugden, David Back, Oliver Lenz, Ludo Lavreys and Thomas Berg. Their work appears in journals such as Antiviral Therapy, Antimicrobial Agents and Chemotherapy, British Journal of Clinical Pharmacology, AIDS and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact